1 / 17

ML141 NEW AND IMPROVED DOCETAXEL INJECTION (TAXOTERE) William Zhao, PhD MBA CEO, Meridian Lab

Meridian Labs 1130 W Lake Cook Rd, Suite 202, Buffalo Grove, IL 60089. ML141 NEW AND IMPROVED DOCETAXEL INJECTION (TAXOTERE) William Zhao, PhD MBA CEO, Meridian Lab. Outline. Introduction/formulation Regulatory strategies Summary Q and A. Introduction. Meridian Lab

ericg
Download Presentation

ML141 NEW AND IMPROVED DOCETAXEL INJECTION (TAXOTERE) William Zhao, PhD MBA CEO, Meridian Lab

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Meridian Labs 1130 W Lake Cook Rd, Suite 202, Buffalo Grove, IL 60089 ML141NEW AND IMPROVED DOCETAXEL INJECTION(TAXOTERE)William Zhao, PhD MBACEO, Meridian Lab www.meridian-lab.com

  2. Outline • Introduction/formulation • Regulatory strategies • Summary • Q and A www.meridian-lab.com

  3. Introduction • Meridian Lab • Headquarters: Buffalo Grove, IL • Labs: Nanjing, China • Focus • Commercialize lead candidate ML141 in US and EU • Proprietary PS80-free formulation of Taxotere • Proprietary PS80-free formulation of Cabazitaxel www.meridian-lab.com

  4. Taxotere and Jevtana • Taxotere: Docetaxel with PS80* • Chemotherapy for Breat, lung, prostate, stomach, and head and neck cancer. • Jevtana: Cabazitaxel with PS80* • Chemotherapy for prostate cancer. • Sales • Taxotere sales $3B before patent expired • Jevtana $450MM annual sales * Polysorbate-80 www.meridian-lab.com

  5. Taxotere and Jevtana Unmet needs for improvement • Safety concerns: Hypersensitivity, fluid retention (Black Box Warning) • Contraindicated if history of severe hypersensitivity reactions to API or to drugs formulated with polysorbate 80 • Steroid pretreatment required • Reconstitution required for the two-vial formulation * Polysorbate-80 www.meridian-lab.com

  6. ML141/ML181 Characteristics • PS80-free docetaxel • SBECD/Captisol as solubilizing agent • Liquid formulation • IV, single vial • Global Patent www.meridian-lab.com

  7. Competitive Landscape: Docetaxel Approved generics: all contain S80 • Hospira • Accord Healthcare • Actavis Inc • Sandoz • Teva (ex-US) • Apotex (ex-US) • Mylan (ex-US) • Eagle www.meridian-lab.com

  8. Regulatory Strategy: 505(b)(2) • One of the FDA drug approval pathways • Full safety and efficacy • Allow the information to come from the brand drug • Much less expensive and much fasterroute to approval • Allow improvement/modification to the btand drug • Need to create a bridge to the brand drug www.meridian-lab.com

  9. Regulatory Strategy: 505(b)(2) ML141 regulatory package: • Reference Taxotere for efficacy and safety • Same label as Taxotere without warning/references to PS80 • Demonstrate same PK profile as Taxotere • No clinical efficacy/safety study required for submission Same package for ML181 www.meridian-lab.com

  10. Key Pre-clinical Data • Efficacy • Hypersensitivity • Bioequivalence www.meridian-lab.com

  11. Dose-Dependent Efficacy Similar to Taxotere Tumor Volume (NSCLC in nude mice) www.meridian-lab.com

  12. No Evidence of Hypersensitivity Heart Rate Systolic Blood Pressure Canine Model (docetaxel 1.0 mg/kg) ML061 ML061 TAXOTERE TAXOTERE www.meridian-lab.com

  13. Bioequivalence to Taxotere Pharmacokinetics in Rats www.meridian-lab.com

  14. Captisol/Taxons • Studies demonstrated the safety benefit of removing PS80 with Captisol/SBECD • PK profiles not affected, hence bioequivalent • Rapid regulatory submission/approval pathway www.meridian-lab.com

  15. Summary • Only PS80-free docetaxel/cabazitaxel • Patent (US, EU, Japan and China) • Same efficacy and better safety profile • Rapid regulatory path: 505(b)(2) • Simple manufacturing process www.meridian-lab.com

  16. Other PS80 free formulations (Nano technology) Emulation Lipid Albumin Clinical studies showed different PK. None is actively developing due to required safety/efficacy studies Other PS80 Free Formulations 16 www.meridian-lab.com www.meridian-lab.com

  17. Thank You www.meridian-lab.com

More Related